Meeting
2016 ASCO Annual Meeting
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.
Authors
Omid Hamid
The Angeles Clinic and Research Institute, Los Angeles, CA
Omid Hamid , John A. Thompson , Adi Diab , Willeke Ros , Ferry Eskens , Candy Bermingham , Cyril Konto , Hua Long , Ken Liao , Bishu J Ganguly , Catherine Fleener , Susan Pleasic-Williams , Pamela D. Garzone , Premal H. Patel , Tenshang Joh , Dimitry S. A. Nuyten , Anthony B. El-Khoueiry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Other
Clinical Trial Registration Number
NCT02315066
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3079)
DOI
10.1200/JCO.2016.34.15_suppl.3079
Abstract #
3079
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.
First Author: Jermaine Coward
Poster
2018 ASCO Annual Meeting
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
First Author: Breelyn A. Wilky
Poster
2014 ASCO Annual Meeting
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
First Author: Margaret K. Callahan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott